Erstellt von fchar99
Alnylam Pharmace. diskutieren
Alnylam Pharmace.
WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
244,10 €
-0,90 %
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $200.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at HC Wainwright from $395.00 to $400.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $234.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Needham & Company LLC from $200.00 to $275.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Royal Bank of Canada from $235.00 to $250.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Barclays PLC from $236.00 to $291.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Evercore ISI from $210.00 to $260.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at TD Cowen from $260.00 to $282.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Bank of America Co. from $248.00 to $295.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Citigroup Inc. from $227.00 to $291.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Stifel Nicolaus from $215.00 to $295.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at UBS Group AG from $253.00 to $288.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Needham & Company LLC from $275.00 to $320.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Barclays PLC from $291.00 to $295.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Citigroup Inc. from $291.00 to $342.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Raymond James from $242.00 to $275.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Royal Bank of Canada from $265.00 to $300.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $370.00 price target on the stock, up previously from $198.00.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Neueste Beiträge
StockNews_com in Quaker Chemical Corp. diskutieren